Licensing Deals
Oragenics Signs LOI to License CardioDialysis Technology for Brain Disorders
Oragenics Inc. has signed a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology, aiming to combine it with its intranasal neurosteroid candidate ONP-002 for a dual-modality approach to traumatic brain injury and neurodegenerative diseases.
ABVC BioPharma Reports $1.28 Million in Q3 Licensing Revenue, Strengthening High-Margin Business Model
ABVC BioPharma has collected $1.28 million in Q3 licensing revenues from multiple partners, including OncoX BioPharma, demonstrating the profitability of its licensing framework with minimal incremental costs.
ABVC BioPharma Receives $100,000 Milestone Payment in Vitargus Licensing Deal
ABVC BioPharma's latest milestone payment from ForSeeCon Eye Corporation strengthens a licensing agreement potentially worth $63.5 million for Vitargus®, positioning the company to capitalize on the multi-billion dollar global vitreous substitute market.
Datavault AI Achieves 467% Revenue Growth in Q2 2025, Secures Major Licensing Deal and Expands Patent Portfolio
Datavault AI's explosive revenue growth and strategic licensing agreements position the company for significant market expansion in AI-driven data monetization and Web 3.0 technologies.
ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Focus
ABVC BioPharma's recent $100,000 milestone payment from ForSeeCon Eye Corporation underscores the growing commercial interest in its ophthalmology solutions, particularly Vitargus®, and strengthens its position in the global eye care market.
ABVC BioPharma Achieves $150K Milestone in Licensing Strategy, Highlighting Growth in Botanical Therapeutics
ABVC BioPharma's recent $150,000 milestone payment from AiBtl BioPharma underscores the success of its licensing-first strategy and the growing interest in its CNS-focused botanical therapeutics.